LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

AngioDynamics Inc

Slēgts

SektorsVeselības aprūpe

9.42 2.84

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.05

Max

9.43

Galvenie mērījumi

By Trading Economics

Ienākumi

6.3M

-4.4M

Pārdošana

-841K

72M

EPS

-0.08

Peļņas marža

-6.12

Darbinieki

748

EBITDA

-2.1M

-329K

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+69.03% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

4.2M

389M

Iepriekšējā atvēršanas cena

6.58

Iepriekšējā slēgšanas cena

9.42

Ziņu noskaņojums

By Acuity

50%

50%

173 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

AngioDynamics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2024. g. 9. dec. 15:23 UTC

Galvenie tirgus virzītāji

AngioDynamics Shares at 52-Week High After FDA Clears NanoKnife

2024. g. 9. dec. 15:20 UTC

Galvenie tirgus virzītāji

AngioDynamics Shares at 52-Week High After FDA Clears NanoKnife

Salīdzinājums

Cenas izmaiņa

AngioDynamics Inc Prognoze

Cenas mērķis

By TipRanks

69.03% augšup

Prognoze 12 mēnešiem

Vidējais 15.5 USD  69.03%

Augstākais 16 USD

Zemākais 15 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AngioDynamics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

2

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

9 / 9.3Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

173 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AngioDynamics Inc

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.